Pregabalin

Generic Name
Pregabalin
Brand Names
Lyrica, Pregabalin Accord, Pregabalin Pfizer, Pregabalin Sandoz, Pregabalin Mylan, Pregabalin Zentiva
Drug Type
Small Molecule
Chemical Formula
C8H17NO2
CAS Number
148553-50-8
Unique Ingredient Identifier
55JG375S6M
Background

Pregabalin is structurally similar to gamma-aminobutyric acid (GABA) - an inhibitory neurotransmitter. It may be used to manage neuropathic pain, postherpetic neuralgia, and fibromyalgia among other conditions. Although as per the FDA Label the mechanism of action has not been definitively defined, there is evidence that pregabalin exerts its effects by bind...

Indication

Pregabalin is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, neuropathic pain associated with spinal cord injury, and as adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older.

Associated Conditions
Diabetic Peripheral Neuropathic Pain (DPN), Epilepsies, Fibromyalgia, Generalized Anxiety Disorder, Neuropathic Pain, Partial-Onset Seizures, Peripheral Neuropathic Pain, Peripheral neuropathy, Postherpetic Neuralgia
Associated Therapies
-
Clinical Trials
Related News

Pregabalin Epilepsy Add-On Trial

Phase 3
Completed
Conditions
Partial Seizures
First Posted Date
2005-09-01
Last Posted Date
2021-01-22
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
178
Registration Number
NCT00141258
Locations
🇰🇷

Pfizer Investigational Site, Seoul, Korea, Republic of

Pregabalin In Partial Seizures: An Open-Label, International, Multicenter Add-On Therapy Trial.

Phase 4
Completed
Conditions
Seizures
First Posted Date
2005-09-01
Last Posted Date
2021-01-25
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
540
Registration Number
NCT00141427
Locations

Pfizer Investigational Site

To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures

Phase 3
Completed
Conditions
Seizure Disorder, Partial
First Posted Date
2005-09-01
Last Posted Date
2009-11-06
Lead Sponsor
Pfizer
Target Recruit Count
455
Registration Number
NCT00141388
Locations
🇨🇦

Pfizer Investigational Site, Montreal, Quebec, Canada

To Evaluate Long-Term Safety and Efficacy of Pregabalin in the Treatment of Neuropathic Pain After Spinal Cord Injury.

Phase 3
Completed
Conditions
Neuropathic Pain
First Posted Date
2005-09-01
Last Posted Date
2008-01-15
Lead Sponsor
Pfizer
Target Recruit Count
132
Registration Number
NCT00141375
Locations
🇦🇺

Pfizer Investigational Site, NSW, Australia

Safety and Efficacy of Pregabalin in Patients With Diabetic Peripheral Neuropathy.

Phase 3
Completed
Conditions
Diabetic Neuropathy, Painful
First Posted Date
2005-09-01
Last Posted Date
2007-08-17
Lead Sponsor
Pfizer
Target Recruit Count
240
Registration Number
NCT00141401
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy